Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.52%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.54%AUDUSD-1.45%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.86%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.69%CHFJPY-0.68%CADJPY-0.67%NZDJPY-0.66%USDCHF+0.62%GBPUSD-0.62%USDCAD+0.59%EURUSD-0.58%NZDUSD-0.55%AUDSGD-0.51%USDZAR+0.44%AUDDKK-0.44%GBPTRY+0.41%NZDMXN+0.41%USDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%EURZAR+0.29%GBPMXN-0.28%GBPZAR+0.28%USDNOK+0.27%USDTRY+0.21%USDSEK+0.20%CHFNOK+0.20%USDPLN+0.20%EURCNH-0.18%NOKJPY-0.16%USDILS+0.16%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.13%EURNOK+0.13%USDCNH-0.12%USDJPY-0.11%GBPSGD-0.09%EURSGD-0.08%PLNJPY-0.08%GBPNZD-0.08%USDSGD+0.06%EURSEK+0.06%SGDJPY+0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%NZDCHF+0.04%USDCOP-0.04%EURCHF+0.04%EURCZK+0.04%EURNZD-0.03%CADCHF+0.03%USDHKD-0.02%CHFSGD-0.01%NZDCAD+0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.83%XPTUSD-0.74%W1-0.53%C1-0.41%XAUUSD-0.34%GAUUSD-0.34%GAGUSD-0.30%XAGUSD-0.30%HG1-0.25%UKOIL+0.21%S1-0.17%USOIL-0.08%BTCUSD-3.00%ETHUSD+57.77%USDTUSD0.00%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.20%XMRUSDT-1.74%DOGEUSD+55.95%LINKUSD-2.81%XLMUSD-3.27%BCHUSDT-3.12%LTCUSD+47.50%UNIUSD-2.50%SUIUSD-2.33%TONUSD+59.18%HBARUSDT-4.83%TAOUSDT-2.55%AAVEUSD-2.89%ONDOUSDT-4.61%ICPUSDT-1.52%DOTUSDT-3.36%WLDUSDT-3.20%ARBUSDT-5.21%ATOMUSDT-2.01%INJUSDT-6.85%STXUSDT-2.39%PYTHUSDT+0.21%TIAUSDT-2.54%FETUSDT-4.01%JUPUSDT+0.82%SEIUSDT-4.48%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-2.25%POLUSDT-1.58%WIFUSDT-2.25%AXSUSDT-2.47%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-6.30%GALAUSDT-1.65%DYDXUSDT-2.37%ORDIUSDT-2.00%NOTUSDT-0.74%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.52%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.54%AUDUSD-1.45%AUDNZD-0.90%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.86%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.69%CHFJPY-0.68%CADJPY-0.67%NZDJPY-0.66%USDCHF+0.62%GBPUSD-0.62%USDCAD+0.59%EURUSD-0.58%NZDUSD-0.55%AUDSGD-0.51%USDZAR+0.44%AUDDKK-0.44%GBPTRY+0.41%NZDMXN+0.41%USDMXN+0.36%USDTHB+0.33%GBPHKD+0.32%AUDNOK-0.31%EURZAR+0.29%GBPMXN-0.28%GBPZAR+0.28%USDNOK+0.27%USDTRY+0.21%USDSEK+0.20%CHFNOK+0.20%USDPLN+0.20%EURCNH-0.18%NOKJPY-0.16%USDILS+0.16%EURHKD-0.15%USDDKK+0.14%NZDSGD+0.13%CHFSEK+0.13%EURNOK+0.13%USDCNH-0.12%USDJPY-0.11%GBPSGD-0.09%EURSGD-0.08%PLNJPY-0.08%GBPNZD-0.08%USDSGD+0.06%EURSEK+0.06%SGDJPY+0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%NZDCHF+0.04%USDCOP-0.04%EURCHF+0.04%EURCZK+0.04%EURNZD-0.03%CADCHF+0.03%USDHKD-0.02%CHFSGD-0.01%NZDCAD+0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.83%XPTUSD-0.74%W1-0.53%C1-0.41%XAUUSD-0.34%GAUUSD-0.34%GAGUSD-0.30%XAGUSD-0.30%HG1-0.25%UKOIL+0.21%S1-0.17%USOIL-0.08%BTCUSD-3.00%ETHUSD+57.77%USDTUSD0.00%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.20%XMRUSDT-1.74%DOGEUSD+55.95%LINKUSD-2.81%XLMUSD-3.27%BCHUSDT-3.12%LTCUSD+47.50%UNIUSD-2.50%SUIUSD-2.33%TONUSD+59.18%HBARUSDT-4.83%TAOUSDT-2.55%AAVEUSD-2.89%ONDOUSDT-4.61%ICPUSDT-1.52%DOTUSDT-3.36%WLDUSDT-3.20%ARBUSDT-5.21%ATOMUSDT-2.01%INJUSDT-6.85%STXUSDT-2.39%PYTHUSDT+0.21%TIAUSDT-2.54%FETUSDT-4.01%JUPUSDT+0.82%SEIUSDT-4.48%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-2.25%POLUSDT-1.58%WIFUSDT-2.25%AXSUSDT-2.47%EOSUSDT-3.88%IMXUSDT-3.36%FARTCOINUSDT-6.30%GALAUSDT-1.65%DYDXUSDT-2.37%ORDIUSDT-2.00%NOTUSDT-0.74%RONINUSDT-2.92%
AS

AstraZeneca PLC (AZN)

NYSE • Healthcare

$178.76
-$3.51 (-1.9%)
Market closed

November 18, 2026 at 21:00 UTC

Open$180.01
Day Range$178.29 - $181.5
Avg. Volume (3M)2.8M
Market Cap$277.2B
P/E Ratio25.2
52 Week Range
$153.41$212.71
Next EarningsIn 82 daysFeb 9, 2027

Interactive Chart

03:37:07 UTC

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$15.9B100%
Gross Profitminus cost of goods$11.9B75%
Operating Incomeminus R&D and overhead$4.3B27%
Net Incomeminus taxes and the rest$3B19%

In plain terms: out of every $100 in revenue, AstraZeneca PLC keeps $19 as net profit.

Fundamentals & Financials

Revenue (TTM)
$62.1B
Net Income (TTM)
$10.9B
EPS (TTM)
$7.08
ROA (TTM)
9.26%
Current Ratio
1.01
Dividend Yield
0.66%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+0.4%Q2 2026$2.58
+5.2%Q3 2026$2.63
+7.3%Q4 2026$2.79
Next

Feb 9

in 82 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +7.3%

AstraZeneca topped expectations on adjusted EPS while revenue came in line with consensus in the third fiscal quarter of 2026, based on preliminary results reported October 30, 2026. Revenue rose 5.3% to roughly $16.0 billion (up from about $15.2 billion a year ago); in the consensus comparison it was $15.993 billion versus a $16.003 billion estimate (-0.1%, in line). Adjusted EPS of $2.79 topped the $2.60 estimate (+7.3%) and was up from $2.38 a year ago. Profitability included gross profit of about $11.9 billion with gross margin near 75%, and operating income of roughly $4.3 billion at an operating margin of 27.0%. Net income increased 21.4% to about $3.1 billion (up from roughly $2.5 billion a year ago). AstraZeneca generated operating cash flow of roughly $4.7 billion and paid about $1.6 billion in dividends during the quarter. For the next period, consensus calls for EPS of $2.41 on revenue of $16.656 billion.

View full earnings history

About AstraZeneca PLC

AstraZeneca PLC develops and sells prescription medicines as a large pharmaceutical company listed on the NYSE under AZN, spanning discovery, development, manufacturing, and commercialization. Its portfolio generated $58.7 billion in FY2025 revenue across treatments for cancer, cardiovascular, renal and metabolic conditions, COVID-19, and rare diseases.

Name
AstraZeneca PLC
CEO
Pascal Claude Roland Soriot
Industry
Healthcare
Year Founded
1992
Employees
96,100

Today's Snapshot

AI-generated

AZN closed 1.9% below yesterday's close, in line with a weaker sector. AstraZeneca extended its collaboration with Tempus AI, a healthcare-data company.

Trading Volume

Below 10d avg (2.3M)

1.8M

vs S&P 500 Today

Underperforming Market

-1.66%

Updated: November 18, 2026 at 21:07 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
AZN’s modest Buy score reflects mixed internals with a tepid trend and weakening short-term momentum. ADX is subdued, momentum readings are negative and price sits below its 10- and 20-day averages while holding above several medium-term moving averages; the 200-day level is just overhead and the pivot lies above the market, forming nearby resistance. Volatility is moderate and OBV is negative, which undercuts breadth. Technical takeaway: The buy case is tentative — trend and volume do not yet confirm a clean recovery.
All signals
  • EMA (5 indicators)$172.94 - $182.86
    Buy
  • RSI (14)51.03
    Neutral
  • Stochastic %K (14, 3, 3)38.61
    Neutral
  • MACD Level (12, 26)4.10
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.